Metronomic chemotherapy is well tolerated, less toxic and as effective as standard chemotherapy. Results from the XeNa trial: a randomized phase 2 trial combining vinorelbine and capecitabine in the treatment of advanced HER2 negative breast cancer

A. S. Brems-Eskildsen; S Linnet; Adam Andrzej Luczak; H. Nielsen; P. Vestlev; E. H. Jacobsen; J. Neimann; C. B. Jensen; T. Dongsgaard; S. T. Langkjer

doi:10.1016/S0959-8049(16)31962-1

Metronomic chemotherapy is well tolerated, less toxic and as effective as standard chemotherapy. Results from the XeNa trial: a randomized phase 2 trial combining vinorelbine and capecitabine in the treatment of advanced HER2 negative breast cancer

A. S. Brems-Eskildsen, S Linnet, Adam Andrzej Luczak, H. Nielsen, P. Vestlev, E. H. Jacobsen, J. Neimann, C. B. Jensen, T. Dongsgaard, S. T. Langkjer

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Original language	English
Article number	384
Journal	European Journal of Cancer
Volume	57
Issue number	Suppl. 2
Pages (from-to)	S110
ISSN	0959-8049
DOIs	https://doi.org/10.1016/S0959-8049(16)31962-1
Publication status	Published - 2016
Event	10th European Breast Cancer Conference - Amsterdam, Netherlands Duration: 9 Mar 2016 → 11 Mar 2016 Conference number: 10

Conference

Conference	10th European Breast Cancer Conference
Number	10
Country/Territory	Netherlands
City	Amsterdam
Period	09/03/2016 → 11/03/2016

Access to Document

10.1016/S0959-8049(16)31962-1

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

Brems-Eskildsen, A. S., Linnet, S., Luczak, A. A., Nielsen, H., Vestlev, P., Jacobsen, E. H., Neimann, J., Jensen, C. B., Dongsgaard, T., & Langkjer, S. T. (2016). Metronomic chemotherapy is well tolerated, less toxic and as effective as standard chemotherapy. Results from the XeNa trial: a randomized phase 2 trial combining vinorelbine and capecitabine in the treatment of advanced HER2 negative breast cancer. European Journal of Cancer, 57(Suppl. 2), S110. Article 384. https://doi.org/10.1016/S0959-8049(16)31962-1

Brems-Eskildsen, A. S. ; Linnet, S ; Luczak, Adam Andrzej et al. / Metronomic chemotherapy is well tolerated, less toxic and as effective as standard chemotherapy. Results from the XeNa trial : a randomized phase 2 trial combining vinorelbine and capecitabine in the treatment of advanced HER2 negative breast cancer. In: European Journal of Cancer. 2016 ; Vol. 57, No. Suppl. 2. pp. S110.

@article{b0fc84416f9f4953a86a078b3be6bbb6,

title = "Metronomic chemotherapy is well tolerated, less toxic and as effective as standard chemotherapy. Results from the XeNa trial: a randomized phase 2 trial combining vinorelbine and capecitabine in the treatment of advanced HER2 negative breast cancer",

author = "Brems-Eskildsen, {A. S.} and S Linnet and Luczak, {Adam Andrzej} and H. Nielsen and P. Vestlev and Jacobsen, {E. H.} and J. Neimann and Jensen, {C. B.} and T. Dongsgaard and Langkjer, {S. T.}",

year = "2016",

doi = "10.1016/S0959-8049(16)31962-1",

language = "English",

volume = "57",

pages = "S110",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Pergamon Press",

number = "Suppl. 2",

note = "10th European Breast Cancer Conference ; Conference date: 09-03-2016 Through 11-03-2016",

}

Brems-Eskildsen, AS, Linnet, S, Luczak, AA, Nielsen, H, Vestlev, P, Jacobsen, EH, Neimann, J, Jensen, CB, Dongsgaard, T & Langkjer, ST 2016, 'Metronomic chemotherapy is well tolerated, less toxic and as effective as standard chemotherapy. Results from the XeNa trial: a randomized phase 2 trial combining vinorelbine and capecitabine in the treatment of advanced HER2 negative breast cancer', European Journal of Cancer, vol. 57, no. Suppl. 2, 384, pp. S110. https://doi.org/10.1016/S0959-8049(16)31962-1

Metronomic chemotherapy is well tolerated, less toxic and as effective as standard chemotherapy. Results from the XeNa trial: a randomized phase 2 trial combining vinorelbine and capecitabine in the treatment of advanced HER2 negative breast cancer. / Brems-Eskildsen, A. S.; Linnet, S; Luczak, Adam Andrzej et al.
In: European Journal of Cancer, Vol. 57, No. Suppl. 2, 384, 2016, p. S110.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

TY - ABST

T1 - Metronomic chemotherapy is well tolerated, less toxic and as effective as standard chemotherapy. Results from the XeNa trial

T2 - 10th European Breast Cancer Conference

AU - Brems-Eskildsen, A. S.

AU - Linnet, S

AU - Luczak, Adam Andrzej

AU - Nielsen, H.

AU - Vestlev, P.

AU - Jacobsen, E. H.

AU - Neimann, J.

AU - Jensen, C. B.

AU - Dongsgaard, T.

AU - Langkjer, S. T.

N1 - Conference code: 10

PY - 2016

Y1 - 2016

U2 - 10.1016/S0959-8049(16)31962-1

DO - 10.1016/S0959-8049(16)31962-1

M3 - Conference abstract in journal

SN - 0959-8049

VL - 57

SP - S110

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - Suppl. 2

M1 - 384

Y2 - 9 March 2016 through 11 March 2016

ER -

Brems-Eskildsen AS, Linnet S, Luczak AA, Nielsen H, Vestlev P, Jacobsen EH et al. Metronomic chemotherapy is well tolerated, less toxic and as effective as standard chemotherapy. Results from the XeNa trial: a randomized phase 2 trial combining vinorelbine and capecitabine in the treatment of advanced HER2 negative breast cancer. European Journal of Cancer. 2016;57(Suppl. 2):S110. 384. doi: 10.1016/S0959-8049(16)31962-1